Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
International Journal of Molecular Sciences · 08.04.2023 · 24 (8) · 6945
DOI: 10.3390/ijms24086945 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.04.2023. Verfasst von Gyöngyi Munkácsy und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Laboratory for Drug Research and Development, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with clinical features of high metastatic potential, susceptibility to relapse, and poor prognosis. TNBC lacks the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is characterized by genomic and transcriptional heterogeneity and a tumor microenvironment (TME) with the presence of high levels of stromal tumor-infiltrating lymphocytes (TILs), immunogenicity, and an important immunosuppressive landscape. Recent evidence suggests that metabolic changes in the TME play a key role in molding tumor development by impacting the stromal and immune cell fractions, TME composition, and activation. Hence, a complex inter-talk between metabolic and TME signaling in TNBC exists, highlighting the possibility of uncovering and investigating novel therapeutic targets. A better understanding of the interaction between the TME and tumor cells, and the underlying molecular mechanisms of cell–cell communication signaling, may uncover additional targets for better therapeutic strategies in TNBC treatment. In this review, we aim to discuss the mechanisms in tumor metabolic reprogramming, linking these changes to potential targetable molecular mechanisms to generate new, physical science-inspired clinical translational insights for the cure of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Laboratory for Drug Research and Development, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary.
- Oncology Biomarker Research Group, Research Centre for Natural Sciences, Institute of Enzymology, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary.
- Seagen, Dammstrasse 23, 6300 Zug, Switzerland.
- Department of Bioinformatics, Semmelweis University, Tűzoltó u. 5-7, 1094 Budapest, Hungary.
- Department of Pediatrics, Semmelweis University, Tűzoltó u. 5-7, 1094 Budapest, Hungary.
ORCID-Profile: Gyöngyi Munkácsy
Förderung
- National Research, Development and Innovation Office
Zitieren
APA
Munkácsy, G., Santarpia, L., & Győrffy, B. (2023). Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 24(8), 6945. https://doi.org/10.3390/ijms24086945
Vancouver
Munkácsy G, Santarpia L, Győrffy B. Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2023;24(8):6945. doi:10.3390/ijms24086945
BibTeX
@article{Munkcsy2023,
author = {Munkácsy, Gyöngyi and Santarpia, Libero and Győrffy, Balázs},
title = {Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {8},
pages = {6945},
doi = {10.3390/ijms24086945}
}
EUVIMED